Personalized Stem Cells’ New Trial Tests Adipose Stem Cell Therapy for Chronic Mild Traumatic Brain Injury

The pilot will evaluate intravenous PSC-05 in people with persistent symptoms after chronic mild traumatic brain injury, tracking adverse events and post-concussive symptoms through Day 90.

Personalized Stem Cells, Inc. is sponsoring a Phase 1 pilot study of PSC-05 in people with persistent symptoms after mild traumatic brain injury. The investigational therapy uses stem cells grown from each participant’s own fat tissue and is given by intravenous injection.

Through day 90, researchers will track adverse events starting at enrollment and assess post-concussion symptoms starting on the day of treatment using the Neurobehavioral Symptom Inventory.

  • Sponsor: Personalized Stem Cells, Inc.
  • Phase/Status: Phase 1, enrolling by invitation
  • Indication: Mild traumatic brain injury with persistent neurobehavioral symptoms related to chronic mTBI; planned enrollment of 10 participants
  • Arms/Dosing: Investigational arm receives PSC-05, an autologous adipose-derived stem cell therapy product given as an intravenous injection of culture-expanded adipose stem cells
  • Control: None
  • Endpoints: Primary: adverse event rate from enrollment to Day 90, end of study. Secondary: Neurobehavioral Symptom Inventory measure of post-concussive symptoms from treatment Day 0 to Day 90, end of study
  • Timing: Actual start November 1, 2026; estimated primary completion May 31, 2027; estimated study completion July 31, 2027

NCT07923487

Want to keep up on regenerative medicine? Get the weekly newsletter here.

Discussion

Sign in to join the discussion.

Similar stories